STRATEGY OF GENE THERAPY AGAINST OVARIAN CANCER BY USING HGF ANTAGONIST(HGF/NK4)

点击翻译按钮获取中文摘要

TO OUR REGRET, IT WAS IMPOSSIBLE TO MAKE EFFECTIVE ADENOVIRAL VECTOR CONTAINING NK4 WHICH IS ANTAGONIST OF HGF (HEPATOCYTE GROWTH FACTOR). SO, WE COULD NOT HELP CHANGING THE PROJECT. IN THIS STUDY, WE INVESTIGATED THE SERUM HGF LEVELS OF THE PATIENTS WITH VARIOUS OVARIAN TUMORS. [MATERIALS AND METHODS] THE BLOOD SAMPLES WERE OBTAINED FROM THE THIRTEEN PATIENTS WITH OVARIAN CANCERS, EIGHT PATIENTS WITH BENIGN OVARIAN TUMORS AND TEN NORMAL VOLUNTEERS. THE SERUM HGF LEVELS WERE DETERMINED BY ELIZA METHODS. INFORMED CONCENTS WERE OBTAINED BY ALL PEARSONS. [RESULTS] THE SERUM HGF LEVEL WAS 0.59 ± 0.38 IN YHE PATIENTS WITH OVARIAN CANCERS, 0.39 ± 0.17 IN YHE PATIENTS WITH BENIGN OVARIANTUMORS AND 0.32 ± 0.06 IN THE NORMAL VOLUNTEERS. THE SERUM HGF LEVEL IN YHE PATIENTS WITH OVARIAN CANCERS WAS CLEARLY HIGHER THAN THAT IN THE NORMAL VOLUNTEERS (P=0.002) THER WAS NO DIFFERENCE BETWEEN THE SERUM HGF LEVEL IN YHE PATIENTS WITH BENIGN OVARIAN TUMORS AND THAT IN THE NORMAL VOLUNTEERS (P=0.25). [CONCULUSION] THE SERUM HGF LEVEL CAN BE ONE OF THE USEFUL MARKER FOR THE OVARIAN CANCER SCREENING.